3 results
Approved WMOCompleted
Demonstrate an increase of 2-year overall survival (OS) of 15 % (from 50% to 65 %) vs historical controls of the addition of nitroglycerin to radiotherapy (±chemotherapy) of stage I-IV NSCLC.
Approved WMOCompleted
The addition of NTG patches to bevacizumab containing chemotherapy (experimental arm) improves PFS in patients with stage IV non-squamous NSCLC, compared to bevacizumab containing chemotherapy without NTG (control arm)Secondary Objectives: Objective…
Approved WMOCompleted
The primary objective is to evaluate the effect of UDCA and ezetimibe on cholesterol elimination assessed as total faecal sterol concentration. Secondary objective is to assess the effect of UDCA and ezetimibe on plasma lipid profile/composition.